Transplanted neurons develop disease-like pathology in Huntington's patients

This study, conducted jointly by Dr. Francesca Cicchetti of Université Laval in Quebec, Canada, Dr. Thomas B. Freeman of the University of South Florida, USA, and colleagues provides the first demonstration that transplanted cells fail to offer a long-term replacement for degenerating neurons in patients with Huntington's disease.

Huntington's disease is a neurodegenerative disease of genetic origin that targets a particular type of neuron. The loss of these neurons is responsible for the appearance of involuntary movements as well as cognitive and psychiatric impairments. Over a decade ago, Dr. Thomas Freeman of the University of South Florida initiated a clinical trial of neural cell transplantation in Huntington's diseased patients in an attempt to alleviate the dreadful symptoms that characterize this disease.

Some patients demonstrated some mild, transient clinical benefits that lasted for about 2 years. However, the loss of functional recovery after this indicated that graft survival and functionality may be jeopardized long- term.

This post-mortem study of 3 cases is the first demonstration that 1) graft survival is indeed attenuated long-term, 2) grafts undergo degeneration that resembles the pathology observed in Huntington's disease, and 3) the brain's inflammatory response could contribute to the compromised survival of grafted cells. The authors also demonstrated that cortical neurons that develop Huntington's disease synapse on the grafts and may cause neurotoxicity to healthy cells, inducing grafted neuronal cell death.

Despite the excitement regarding cell transplantation therapy utilizing embryonic or stem cells, these results raise concerns for the therapeutic potential of transplantation as a treatment option for Huntington's disease. However, these observations suggest new potential mechanisms involved in the development of the disease. A more in-depth investigation could lead to the development of novel therapeutic strategies. The control of patient immune and inflammatory responses holds therapeutic potential, and Cicchetti et al. are continuing their research in that direction.

Dr. Francesca Cicchetti is a professor in the Department of Psychiatry/Neuroscience at Université Laval and a researcher in neurobiology at le Centre hospitalier universitaire de Québec. She is directing a research laboratory focused on understanding neuronal degeneration and developing therapeutic strategies for neurodegenerative diseases.

Dr. Thomas B. Freeman is a neurosurgeon, director of clinical research, and medical director of the Center of Excellence for Aging and Brain Repair at the University of South Florida.

This work includes the scientific contribution of the following authors:
Samuel Saporta (University of South Florida)
Robert Hauser (Parkinson's Disease and Movement Disorders Center, National Parkinson's Foundation Center of Excellence, University of South Florida)
Martin Parent (Groupe de recherche sur le système nerveux central [GRSNC])
Martine Saint-Pierre (Centre de Recherche du CHUL [CHUQ])
Paul Sanberg (University of South Florida)
Xiao Li (Emory University School of Medicine)
John Parker (University of Louisville Health Sciences Center)
Yaping Chu (Rush University Medical Center)
Elliot Mufson (Rush University Medical Center)
Jeffrey Kordower (Rush University Medical Center)
Information:
Francesca Cicchetti
Centre de Recherche du CHUL (CHUQ), Unité de Neurosciences,Canada
Université Laval
Tel.: 418-656-4141, ext. 48853
Tel.:418-262-9122
Francesca.Cicchetti@crchul.ulaval.ca
Thomas B. Freeman,
University of South Florida, USA
Tel.: 813-259-0889
Tel.: 813-389-0679 tfreeman@health.usf.edu